| 书目名称 | The Evaluation of Surrogate Endpoints |
| 编辑 | Tomasz Burzykowski,Geert Molenberghs,Marc Buyse |
| 视频video | http://file.papertrans.cn/910/909262/909262.mp4 |
| 概述 | Covers the latest research on a sensitive and controversial topic in a rpofessional and well researched manner.Provides practical outlook as well as model guidelines and software tools that should be |
| 丛书名称 | Statistics for Biology and Health |
| 图书封面 |  |
| 描述 | .Both humanitarian and commercial considerations have spurred intensive search for methods to reduce the time and cost required to develop new therapies. The identification and use of surrogate endpoints, i.e., measures that can replace or supplement other endpoints in evaluations of experimental treatments or other interventions, is a general strategy that has stimulated both enthusiasm and skepticism. Surrogate endpoints are useful when they can be measured earlier, more conveniently, or more frequently than the "true" endpoints of primary interest. Regulatory agencies around the globe, particularly in the United States, Europe, and Japan, are introducing provisions and policies relating to the use of surrogate endpoints in registration studies. But how can one establish the adequacy of a surrogate? What kind of evidence is needed, and what statistical methods portray that evidence most appropriately? ..This book offers a balanced account on this controversial topic. The text presents major developments of the last couple of decades, together with a unified, meta-analytic framework within which surrogates can be evaluated from several angles. Methodological development is coupled |
| 出版日期 | Book 2005 |
| 关键词 | cancer; data analysis; dermatology; diseases; oncology; statistics; therapy |
| 版次 | 1 |
| doi | https://doi.org/10.1007/b138566 |
| isbn_softcover | 978-1-4419-1906-9 |
| isbn_ebook | 978-0-387-27080-7Series ISSN 1431-8776 Series E-ISSN 2197-5671 |
| issn_series | 1431-8776 |
| copyright | Springer-Verlag New York 2005 |
|Archiver|手机版|小黑屋|
派博传思国际
( 京公网安备110108008328)
GMT+8, 2025-8-16 18:23
发表于 2025-3-21 19:49:10
